Survivin expression in acute leukemias and myelodysplastic syndromes

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

We analyzed by immunocytochemistry the expression of survivin in bone marrow cells from 36 acute myeloid leukemia (AML) cases, from 98 patients with myelodysplastic syndrome (MDS), and from 41 non hemopathic subjects. Our aim was to evaluate whether abnormalites in survivin expression were associated with peculiar laboratory and clinical findings, altered apoptosis levels or altered proliferative rate. In normal samples survivin was never detectable. It was detected in almost all AML and MDS cases. In AML and in MDS with more than 5% bone marrow blasts survivin levels higher than in RA and RARS were observed (P = 0.04). In MDS a tendential inverse correlation between survivin and TUNEL positivity was identified (P = 0.08), whereas survivin expression was independent of the proliferative rate. Survivin levels did not predict disease progression in MDS; among AML patients treated with intensive polichemotherapy, survivin expression was significantly higher in resistant cases (P = 0.01). Our findings confirm the high incidence of survivin expression in AML. Its abnormal expression also in MDS may play a role in promoting aberrantly increased cell viability and contribute to the altered homeostatic balance between cell growth and cell death.

Original languageEnglish
Pages (from-to)2229-2237
Number of pages9
JournalLeukemia and Lymphoma
Volume45
Issue number11
DOIs
Publication statusPublished - Nov 2004

Fingerprint

Myelodysplastic Syndromes
Leukemia
Acute Myeloid Leukemia
In Situ Nick-End Labeling
Bone Marrow Cells
Disease Progression
Cell Survival
Cell Death
Bone Marrow
Immunohistochemistry
Apoptosis
Incidence
Growth

Keywords

  • Acute leukemia
  • Apoptosis
  • Immunocytochemistry
  • Myelodysplastic syndrome
  • Survivin

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Survivin expression in acute leukemias and myelodysplastic syndromes. / Invernizzi, Rosangela; Travaglino, Erica; Lunghi, Monia; Klersy, Catherine; Bernasconi, Paolo; Cazzola, Mario; Ascari, Edoardo.

In: Leukemia and Lymphoma, Vol. 45, No. 11, 11.2004, p. 2229-2237.

Research output: Contribution to journalArticle

@article{01565297ecd34fe28c01a6f53d474021,
title = "Survivin expression in acute leukemias and myelodysplastic syndromes",
abstract = "We analyzed by immunocytochemistry the expression of survivin in bone marrow cells from 36 acute myeloid leukemia (AML) cases, from 98 patients with myelodysplastic syndrome (MDS), and from 41 non hemopathic subjects. Our aim was to evaluate whether abnormalites in survivin expression were associated with peculiar laboratory and clinical findings, altered apoptosis levels or altered proliferative rate. In normal samples survivin was never detectable. It was detected in almost all AML and MDS cases. In AML and in MDS with more than 5{\%} bone marrow blasts survivin levels higher than in RA and RARS were observed (P = 0.04). In MDS a tendential inverse correlation between survivin and TUNEL positivity was identified (P = 0.08), whereas survivin expression was independent of the proliferative rate. Survivin levels did not predict disease progression in MDS; among AML patients treated with intensive polichemotherapy, survivin expression was significantly higher in resistant cases (P = 0.01). Our findings confirm the high incidence of survivin expression in AML. Its abnormal expression also in MDS may play a role in promoting aberrantly increased cell viability and contribute to the altered homeostatic balance between cell growth and cell death.",
keywords = "Acute leukemia, Apoptosis, Immunocytochemistry, Myelodysplastic syndrome, Survivin",
author = "Rosangela Invernizzi and Erica Travaglino and Monia Lunghi and Catherine Klersy and Paolo Bernasconi and Mario Cazzola and Edoardo Ascari",
year = "2004",
month = "11",
doi = "10.1080/10428190412331283251",
language = "English",
volume = "45",
pages = "2229--2237",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "11",

}

TY - JOUR

T1 - Survivin expression in acute leukemias and myelodysplastic syndromes

AU - Invernizzi, Rosangela

AU - Travaglino, Erica

AU - Lunghi, Monia

AU - Klersy, Catherine

AU - Bernasconi, Paolo

AU - Cazzola, Mario

AU - Ascari, Edoardo

PY - 2004/11

Y1 - 2004/11

N2 - We analyzed by immunocytochemistry the expression of survivin in bone marrow cells from 36 acute myeloid leukemia (AML) cases, from 98 patients with myelodysplastic syndrome (MDS), and from 41 non hemopathic subjects. Our aim was to evaluate whether abnormalites in survivin expression were associated with peculiar laboratory and clinical findings, altered apoptosis levels or altered proliferative rate. In normal samples survivin was never detectable. It was detected in almost all AML and MDS cases. In AML and in MDS with more than 5% bone marrow blasts survivin levels higher than in RA and RARS were observed (P = 0.04). In MDS a tendential inverse correlation between survivin and TUNEL positivity was identified (P = 0.08), whereas survivin expression was independent of the proliferative rate. Survivin levels did not predict disease progression in MDS; among AML patients treated with intensive polichemotherapy, survivin expression was significantly higher in resistant cases (P = 0.01). Our findings confirm the high incidence of survivin expression in AML. Its abnormal expression also in MDS may play a role in promoting aberrantly increased cell viability and contribute to the altered homeostatic balance between cell growth and cell death.

AB - We analyzed by immunocytochemistry the expression of survivin in bone marrow cells from 36 acute myeloid leukemia (AML) cases, from 98 patients with myelodysplastic syndrome (MDS), and from 41 non hemopathic subjects. Our aim was to evaluate whether abnormalites in survivin expression were associated with peculiar laboratory and clinical findings, altered apoptosis levels or altered proliferative rate. In normal samples survivin was never detectable. It was detected in almost all AML and MDS cases. In AML and in MDS with more than 5% bone marrow blasts survivin levels higher than in RA and RARS were observed (P = 0.04). In MDS a tendential inverse correlation between survivin and TUNEL positivity was identified (P = 0.08), whereas survivin expression was independent of the proliferative rate. Survivin levels did not predict disease progression in MDS; among AML patients treated with intensive polichemotherapy, survivin expression was significantly higher in resistant cases (P = 0.01). Our findings confirm the high incidence of survivin expression in AML. Its abnormal expression also in MDS may play a role in promoting aberrantly increased cell viability and contribute to the altered homeostatic balance between cell growth and cell death.

KW - Acute leukemia

KW - Apoptosis

KW - Immunocytochemistry

KW - Myelodysplastic syndrome

KW - Survivin

UR - http://www.scopus.com/inward/record.url?scp=8644241716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8644241716&partnerID=8YFLogxK

U2 - 10.1080/10428190412331283251

DO - 10.1080/10428190412331283251

M3 - Article

C2 - 15512811

AN - SCOPUS:8644241716

VL - 45

SP - 2229

EP - 2237

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 11

ER -